Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora

Drug Metabolism and Disposition

Volumn 40, Issue 8, 2012, Pages 1538-1544

  Yang, Zhen ^a   Wang, Jing Rong ^c   Niu, Tao ^a   Gao, Song ^a   Yin, Taijun ^a   You, Ming ^b   Jiang, Zhi Hong ^c   Hu, Ming ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMPOUND K; DRUG METABOLITE; GINSENG EXTRACT; GINSENOSIDE; GLYCOPROTEIN P; PROTOPANAXADIOL; PROTOPANAXATRIOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOTRANSFORMATION; CELL LEVEL; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; INTESTINE FLORA; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

MUS; PANAX GINSENG;

EID: 84863960161     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.044008     Document Type: Article

References (36)

1. Akao T, Kanaoka M, and Kobashi K (1998a) Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration-measurement of compound K by enzyme immunoassay. Biol Pharm Bull 21:245-249.
2. Akao T, Kida H, Kanaoka M, Hattori M, and Kobashi K (1998b) Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol 50:1155-1160.
3. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding. Science 323:1718-1722.
4. Bae EA, Park SY, and Kim DH (2000) Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull 23:1481-1485.
5. Bae EA, Shin JE, and Kim DH (2005) Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect. Biol Pharm Bull 28:1903-1908.
6. Chae S, Kang KA, Chang WY, Kim MJ, Lee SJ, Lee YS, Kim HS, Kim DH, and Hyun JW (2009) Effect of compound K, a metabolite of ginseng saponin, combined with gamma-ray radiation in human lung cancer cells in vitro and in vivo. J Agric Food Chem 57:5777-5782.
7. Chen L, Li Y, Zhao Q, Peng H, and Hou T (2011) ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques. Mol Pharm 8:889-900.
8. del Amo EM, Heikkinen AT, and Mönkkönen J (2009) In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption. Eur J Pharm Sci 36:200-211.
9. Engman HA, Lennernäs H, Taipalensuu J, Otter C, Leidvik B, and Artursson P (2001) CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies. J Pharm Sci 90:1736-1751.
10. Hasegawa H, Matsumiya S, Murakami C, Kurokawa T, Kasai R, Ishibashi S, and Yamasaki K (1994) Interactions of ginseng extract, ginseng separated fractions, and some triterpenoid saponins with glucose transporters in sheep erythrocytes. Planta Med 60:153-157.
11. Hu M and Borchardt RT (1990) Mechanism of L-alpha-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2). Pharm Res 7:1313-1319.
12. Hu M and Borchardt RT (1992) Transport of a large neutral amino acid in a human intestinal epithelial cell line (Caco-2): uptake and efflux of phenylalanine. Biochim Biophys Acta 1135:233-244.
13. Hu M, Chen J, Tran D, Zhu Y, and Leonardo G (1994) The Caco-2 cell monolayers as an intestinal metabolism model: metabolism of dipeptide Phe-Pro. J Drug Target 2:79-89.
14. Hu M, Li Y, Davitt CM, Huang SM, Thummel K, Penman BW, and Crespi CL (1999) Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm Res 16:1352-1359.
15. Joo KM, Lee JH, Jeon HY, Park CW, Hong DK, Jeong HJ, Lee SJ, Lee SY, and Lim KM (2010) Pharmacokinetic study of ginsenoside Re with pure ginsenoside Re and ginseng berry extracts in mouse using ultra performance liquid chromatography/mass spectrometric method. J Pharm Biomed Anal 51:278-283.
16. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, and van Tellingen O (2004) The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 53:173-178.
17. Kim AD, Kang KA, Zhang R, Lim CM, Kim HS, Kim DH, Jeon YJ, Lee CH, Park J, Chang WY, et al. (2010) Ginseng saponin metabolite induces apoptosis in MCF-7 breast cancer cells through the modulation of AMP-activated protein kinase. Environ Toxicol Pharmacol 30:134-140.
18. Kusuhara H and Sugiyama Y (2002) Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release 78:43-54.
19. Lee PS, Song TW, Sung JH, Moon DC, Song S, and Chung YB (2006) Pharmacokinetic characteristics and hepatic distribution of IH-901, a novel intestinal metabolite of ginseng saponin, in rats. Planta Med 72:204-210.
20. Li W, Liu Y, Zhang JW, Ai CZ, Xiang N, Liu HX, and Yang L (2009) Anti-androgen-independent prostate cancer effects of ginsenoside metabolites in vitro: mechanism and possible structure-activity relationship investigation. Arch Pharm Res 32:49-57.
21. Liu H, Yang J, Du F, Gao X, Ma X, Huang Y, Xu F, Niu W, Wang F, Mao Y, et al. (2009) Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab Dispos 37:2290-2298.
22. Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, and Schellens JH (1998) Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352:285.
23. Musende AG, Eberding A, Wood C, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, and Guns ET (2009) Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer Chemother Pharmacol 64:1085-1095.
24. Paek IB, Moon Y, Kim J, Ji HY, Kim SA, Sohn DH, Kim JB, and Lee HS (2006) Pharmacokinetics of a ginseng saponin metabolite compound K in rats. Biopharm Drug Dispos 27:39-45.
25. Qian T, Cai Z, Wong RN, Mak NK, and Jiang ZH (2005) In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J Chromatogr B Analyt Technol Biomed Life Sci 816:223-232.
26. Raeissi SD, Hidalgo IJ, Segura-Aguilar J, and Artursson P (1999) Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm Res 16:625-632.
27. Shin HY, Park SY, Sung JH, and Kim DH (2003) Purification and characterization of alpha-L-arabinopyranosidase and alpha-L-arabinofuranosidase from Bifidobacterium breve K-110, a human intestinal anaerobic bacterium metabolizing ginsenoside Rb2 and Rc. Appl Environ Microbiol 69:7116-7123.
28. Tawab MA, Bahr U, Karas M, Wurglics M, and Schubert-Zsilavecz M (2003) Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos 31:1065-1071.
29. van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, Rooswinkel RW, van Tellingen O, Rosing H, Beijnen JH, et al. (2009) Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 69:8996-9002.
30. Wang CZ, Du GJ, Zhang Z, Wen XD, Calway T, Zhen Z, Musch MW, Bissonnette M, Chang EB, and Yuan CS (2012) Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human colorectal cancer. Int J Oncol 40:1970-1976.
31. Xu QF, Fang XL, and Chen DF (2003) Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 84:187-192.
32. Yan Y, Cook J, McQuillan J, Zhang G, Hitzman CJ, Wang Y, Wiedmann TS, and You M (2007) Chemopreventive effect of aerosolized polyphenon E on lung tumorigenesis in A/J mice. Neoplasia 9:401-405.
33. Yang Z, Gao S, Wang J, Yin T, Teng Y, Wu B, You M, Jiang Z, and Hu M (2011) Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. Drug Metab Dispos 39:1866-1872.
34. Yang Z, Gao S, Yin T, Kulkarni KH, Teng Y, You M, and Hu M (2010) Biopharmaceutical and pharmacokinetic characterization of matrine as determined by a sensitive and robust UPLC-MS/ MS method. J Pharm Biomed Anal 51:1120-1127.
35. Yoo MH, Yeom SJ, Park CS, Lee KW, and Oh DK (2011) Production of aglycon protopanaxadiol via compound K by a thermostable β-glycosidase from Pyrococcus furiosus. Appl Microbiol Biotechnol 89:1019-1028.
36. Zhang Z, Futamura M, Vikis HG, Wang M, Li J, Wang Y, Guan KL, and You M (2003) Positional cloning of the major quantitative trait locus underlying lung tumor susceptibility in mice. Proc Natl Acad Sci USA 100:12642-12647.